RT Journal Article
SR Electronic
T1 Long-Term Opioid Use and Emotional, Cognitive, and Sensorimotor Function in Chronic Back Pain
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.14.22279907
DO 10.1101/2022.09.14.22279907
A1 Rached, Gaelle
A1 Vigotsky, Andrew D.
A1 Branco, Paulo
A1 Jabakhanji, Rami
A1 Schnitzer, Thomas J.
A1 Vania Apkarian, A.
A1 Baliki, Marwan N.
YR 2024
UL http://medrxiv.org/content/early/2024/01/09/2022.09.14.22279907.abstract
AB This study examines cognitive, emotional, sensory, and motor function in patients with chronic back pain (CBP) with and without long-term opioid exposure (CBP+O vs. CBP−O) and the influence of race and sex on these outcomes. We recruited 64 CBP+O (mean 7.4 years of opioid use) and 64 matched CBP−O. We collected pain intensity, pain duration, NIH Toolbox outcomes, and measures of opioid use: dosage, duration, blood levels, and withdrawal symptoms. We compared both groups to a normative sample, examined sex and race influences separately, and related CBP+O’s NIH Toolbox outcomes to their opioid use measures.CBP+O reported greater pain interference and poorer emotional function. Sex moderated opioid exposure’s effects on cognitive performance and social satisfaction, while race moderated motor dexterity and taste outcomes. In CBP+O, 1) opioid dosage was associated with cognitive speed and sensory performance; 2) blood levels of opioids corresponded with poorer attention, motor endurance, and more severe stress and negative affect; 3) opioid use duration was related to improved working memory; while 4) higher withdrawal symptoms were associated with poorer cognitive performance, worsened negative emotions, and decreased grip strength.The study demonstrates both positive and negative outcomes associated with long-term opioid use in CBP, highlighting the need to consider sex- and race-related factors when assessing function in this population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is funded by the National Institute of Drug Abuse at National Institutes of Health (1P50DA044121) and the National Institute Of Neurological Disorders And Stroke of the National Institutes of Health under Award Number F31NS126012. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. In addition, this material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE-1324585.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Northwestern University Institutional Review Board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at openpain.org https://www.openpain.org